Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic Leukemia in the United States: A large population-based study

BACKGROUND: Despite approval of azacitidine in 2004 and decitabine in 2006 in the US for chronic myelomonocytic leukemia (CMML), overall survival (OS) benefit with hypomethylating agent (HMA) therapy is unclear. METHODS: We selected older adults (age ≥66 years) diagnosed with CMML during 2001–2011 f...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Cancer
Main Authors: Zeidan, Amer M., Hu, Xin, Long, Jessica B., Wang, Rong, Ma, Xiaomei, Podoltsev, Nikolai, Huntington, Scott F., Gore, Steven D., Davidoff, Amy J.
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2017
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6540984/
https://ncbi.nlm.nih.gov/pubmed/28621841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30814
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla